Monthly Treatment With Subcutaneous Casirivimab/Imdevimab Well Tolerated, Tied To Protection Against COVID-19, Trial Shows
August 02, 2022
Infectious Disease Advisor (8/1, Mermelstein) reports, “Monthly treatment with subcutaneous casirivimab/imdevimab [REGEN‑COV] was well tolerated and associated with significant protection against COVID-19 infection, according to results of a phase 1, doub...